As of 9:30 AM on the 13th, Pamisell is trading at 19,300 KRW, down 3.5% from the previous day. This represents a 6.54% decline compared to June 16. Pamisell is known as a bio-pharmaceutical company that developed the world's first stem cell therapy.
Over the past five days, individual investors have sold a net 468,845 shares, while foreign investors and institutions have bought a net 374,060 shares and 79,663 shares, respectively.

※ This article was generated in real-time by an automated article creation algorithm jointly developed by Asia Economy and the financial AI specialist company Thinkpool.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.

